
Orexo Submits Life-Saving Nasal Medication for Opioid Overdose to FDA
Orexo AB, a pharmaceutical company, has made a significant move in the fight against opioid overdoses by submitting a New Drug Application (NDA) for its lead pharmaceutical pipeline asset, OX124, to the US Food and Drug Administration (FDA). Revolutionary Drug Delivery Platform OX124 is a nasal rescue medication for opioid overdose and is based on…